Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9356126 | 0.86 | HSD17B10 (0.36) | CYP19A1 | |
| SCHEMBL9360186 | 0.84 | SIRT2 (0.40) | CYP19A1 | |
| SCHEMBL20073868 | 0.82 | SIRT2 (0.42) | CYP19A1 | |
| SCHEMBL320036 | 0.79 | MEN1 (0.34) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL18434036 | 0.78 | KDM4E (0.33) | MEN1CYP2C9KMT2ACYP19A1 | |
| SCHEMBL9356226 | 0.78 | HSD17B10 (0.34) | CYP19A1 | |
| SCHEMBL29324533 | 0.74 | — | — | |
| SCHEMBL11846071 | 0.73 | SIRT2 (0.46) | — | |
| SCHEMBL19066495 | 0.73 | — | — | |
| SCHEMBL19767 | 0.72 | CPB2 (0.35) | MEN1CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181274-A | Enolization and ethylization combined reaction method | 中山百灵生物技术股份有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-114181274-A | Enolization and ethylization combined reaction method | 中山百灵生物技术股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2011084439-A1 | TETRAHYDROCARBOLINE DERIVATIVES AS EG5 INHIBITORS | SANOFI (FR) | 2011-07-14 | — | — | WO | disclosed |
| US-7767854-B2 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1884510-A1 | N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-02-06 | — | — | EP | disclosed |
| EP-0310321-B1 | Immunomodulatory azaspiranes | SMITHKLINE BEECHAM CORP (US) | 1994-11-30 | — | — | EP | disclosed |
| WO-1989002889-A1 | IMMUNOMODULATORY AZASPIRANES | SMITHKLINE BECKMAN CORPORATION (US) | 1989-04-06 | — | — | WO | disclosed |
| EP-0310321-A2 | Immunomodulatory azaspiranes | SMITHKLINE BEECHAM CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0209983-A1 | Dialkylaminotetrahydroquinazoline | ELI LILLY AND COMPANY (US) | 1987-01-28 | — | — | EP | disclosed |
| US-4622398-A | INCREASING CONCENTRATION OF DOPAMINE AND NOREPINEPHRINE IN BRAIN, ANTAGONIST | ELI LILLY AND COMPANY (US) | 1986-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | HRH4, HRH2, CNR2 | MEN1 3895/4885CYP2C9 114/4885KMT2A 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.